LAB vs MA · rev $174.4M vs P/E 38, rev $32.79B
Standard Biotools Inc (LAB) versus Mastercard Inc (MA) — a side-by-side from cached financials, not a winner call.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Mastercard Inc (MA) is a credit services company listed on US. It is led by Michael Miebach.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
Latest reported MA revenue for 2025-12-31 was $32.79B. Net income was $14.97B. Revenue was up 16.4% from 2024-12-31 to 2025-12-31. MA currently screens at market cap $515.12B and trailing P/E 38.4.
LAB currently screens at market cap $317.1M. MA currently screens at market cap $515.12B and trailing P/E 38.4.
Not investment advice. Open the LAB and MA stock pages for the full models.
Not investment advice.